Related Experiment Video
Updated: Jun 19, 2025
07:59
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
6.3K
Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
Khandoker Usran Ferdous1,2, Mulu Z Tesfay1,2, Aleksandra Cios1
1Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Biomedicines
|July 27, 2024
Summary
Targeting pancreatic cancer stroma with engineered oncolytic viruses can improve drug delivery. This novel approach enhances viral infiltration and tumor regression in borderline resectable and locally advanced pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents significant treatment challenges, particularly in borderline resectable (BR) and locally advanced (LA) stages.
- Current therapies like chemotherapy and radiation show limited efficacy for BR/LA PDAC.
- Tumor stroma, characterized by dense desmoplastic tissue, impedes the penetration of therapeutic agents, including oncolytic viruses.
Purpose of the Study:
- To investigate the potential of engineered oncolytic viruses to overcome the stromal barrier in PDAC.
- To enhance the delivery and efficacy of oncolytic virotherapy in BR and LA PDAC models.
- To explore a novel strategy for improving tumor resectability in challenging PDAC cases.
Main Methods:
- Engineering oncolytic viruses to express proteolytic enzymes targeting stromal components like hyaluronic acid and collagen.
- Evaluating the enhanced viral distribution and tumor penetration in preclinical PDAC models.
- Assessing the impact of stromal softening on oncolysis and tumor size reduction.
Main Results:
- Engineered oncolytic viruses effectively degraded the desmoplastic stroma.
- Improved viral infiltration and distribution within the PDAC tumor microenvironment were observed.
- Significant tumor size regression and increased oncolysis were achieved.
Conclusions:
- Engineering oncolytic viruses to target tumor stroma represents a promising strategy for treating PDAC.
- This approach can enhance therapeutic agent delivery and improve outcomes for patients with BR and LA PDAC.
- Further development may lead to improved surgical resectability and patient survival.
Related Concept Videos
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:27Tumor Immunotherapy
498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498